Figure 1. Vasopressin in heart failure.
Figure 2. Vasopressin (AVP, ADH).
Figure 3. EVEREST: Three trials in one.
Figure 4. Change in patient-assessed dyspnea at day one in the EVEREST trial.
Figure 5. Physician-assessed symptoms.
Figure 6. Vasopressin antagonists in acute heart failure syndromes.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.